Eliem Therapeutics, Inc. – NASDAQ:ELYM

Add to watchlist

$5.11

-2.10

-29.22%

Market closed

Open in about 17 hours

-15.06%

month

+158.78%

quarter

+161.59%

year

Market Cap	342.67M
Enterprise value	36.35M

P/E	-1.7
EV/Sales	N/A
EV/EBITDA	-0.80
Price/Sales	N/A
Price/Book	0.61
PEG ratio	-0.02
EPS	-0.53

Revenue	N/A
EBITDA	-20.22M
Income	-14.52M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Eliem Therapeutics, Inc. (NASDAQ:ELYM): Profit margin
Jun 2023	0	-5.22M
Sep 2023	0	-3.96M
Dec 2023	0	-3.64M
Mar 2024	0	-1.69M

Eliem Therapeutics Financials Estimate

Q Y

Eliem Therapeutics, Inc. (NASDAQ:ELYM): Analyst Estimates
2027	0	-26.17M

Analysts Price target
Financials & Ratios estimates

Eliem Therapeutics, Inc. (NASDAQ:ELYM): Debt to assets
Jun 2023	116274000	3.77M	3.24%
Sep 2023	112735000	2.99M	2.65%
Dec 2023	110469000	2.87M	2.6%
Mar 2024	109334000	2.95M	2.7%

Eliem Therapeutics, Inc. (NASDAQ:ELYM): Cash Flow
Jun 2023	-7.96M	-1.60M	24K
Sep 2023	3.49M	28.03M	528K
Dec 2023	-947K	36.74M	288K
Mar 2024	-1.81M	13.75M	15K

Eliem Therapeutics alternative data

Eliem Therapeutics, Inc. (NASDAQ:ELYM): Employee count
Aug 2023	30
Sep 2023	30
Oct 2023	30
Nov 2023	30
Dec 2023	30
Jan 2024	30
Feb 2024	30
Apr 2024	30
May 2024	9
Jun 2024	9
Jul 2024	9

Eliem Therapeutics
Hedge Funds Holdings Q1 2023

6.87% -56.27%

of ELYM is owned by hedge funds

8 -12

hedge funds hold ELYM stock

1.80M -14.82M

shares is hold by hedge funds

ELYM hedge funds holdings changes

Eliem Therapeutics
Insider Trading

Eliem Therapeutics, Inc. (NASDAQ:ELYM): Insider trades (number of shares)
Period	Buy	Sel
Jun 2024	0	1245

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	20 Jun 2024	PIMBLETT EMILY officer: CHIEF ACCOUNTING OFFICER officer: CHIEF ACCOUNTING OFFICER	Common Stock	1,245	$7.22	$8,983
Option	18 Jun 2024	PIMBLETT EMILY officer: CHIEF ACCOUNTING OFFICER officer: CHIEF ACCOUNTING OFFICER	Restricted Stock Units	5,000	N/A	N/A
Option	18 Jun 2024	PIMBLETT EMILY officer: CHIEF ACCOUNTING OFFICER officer: CHIEF ACCOUNTING OFFICER	Common Stock	5,000	N/A	N/A
Option	5 Apr 2024	MORISSET VALERIE officer: EVP, R&D..	Common Stock	17,847	N/A	N/A
Option	5 Apr 2024	MORISSET VALERIE officer: EVP, R&D..	Stock Option (Right to Buy)	17,847	N/A	N/A
Option	18 Mar 2024	PIMBLETT EMILY officer: CHIEF ACCOUNTING OFFICER officer: CHIEF ACCOUNTING OFFICER	Restricted Stock Units	40,000	N/A	N/A
Option	20 Sep 2023	MORISSET VALERIE officer: EVP, R&D..	Common Stock	15,297	N/A	N/A
Option	20 Sep 2023	MORISSET VALERIE officer: EVP, R&D..	Common Stock	5,431	$0	$11
Option	20 Sep 2023	MORISSET VALERIE officer: EVP, R&D..	Stock Option (Right to Buy)	15,297	N/A	N/A
Option	20 Sep 2023	MORISSET VALERIE officer: EVP, R&D..	Stock Option (Right to Buy)	5,431	$0	$11

ELYM insider trading transactions

Eliem Therapeutics
Executives

Insider	Age	Compensation
Mr. Robert W. Azelby M.B.A. (1968) Pres, Chief Executive Officer & Director	57	$678,000
Ms. Erin M. Lavelle (1978) Executive Vice President, Chief Operating Officer & Chief Financial Officer	47	$502,880
Ms. Valerie Morisset Ph.D. (1970) Chief Scientific Officer and Executive Vice President of R&D	55	$497,150

Eliem Therapeutics
Latest News

Thursday, 3 October 2024
10:00	Climb Bio to Host Virtual Investor Event on October 15, 2024	globenewswire.com
Wednesday, 2 October 2024
09:00	Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.	globenewswire.com
Wednesday, 11 September 2024
07:00	Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit	globenewswire.com
Monday, 26 August 2024
07:00	Eliem Therapeutics Announces Additions to its Leadership Team	globenewswire.com
Wednesday, 14 August 2024
06:05	Eliem Therapeutics Reports Second Quarter Financial Results	globenewswire.com
Friday, 28 June 2024
13:58	Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value	seekingalpha.com
07:00	Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes	globenewswire.com
Thursday, 27 June 2024
16:01	Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement	globenewswire.com
Monday, 15 April 2024
08:15	SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the Firm	prnewswire.com
Thursday, 11 April 2024
08:30	ELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to Shareholders	businesswire.com
07:00	Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement	globenewswire.com
Friday, 21 July 2023
08:27	Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%	Zacks Investment Research
Thursday, 20 July 2023
08:04	Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today?	InvestorPlace
06:57	Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself	Market Watch
Wednesday, 30 November 2022
07:00	Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference	GlobeNewsWire
Tuesday, 21 June 2022
12:01	5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More	Benzinga
Monday, 13 June 2022
10:49	5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retailer Joins The Leaderboard	Benzinga
Monday, 16 May 2022
11:38	5 Short Squeeze Candidates To Watch This Week: Vertex Energy Tops List, Medavail Holdings And Camping World Remain Elevated	Benzinga
Monday, 25 April 2022
13:45	Eliem Therapeutics shares sink more than 50% after lead program fails to show benefit in clinic	GeekWire
09:06	See Here Why Recently Listed Eliem Therapeutics Shares Are Plummeting	Benzinga
Monday, 21 March 2022
07:00	Eliem Therapeutics to Present at Stifel's 2022 CNS Days	GlobeNewsWire
Friday, 11 February 2022
07:00	Eliem Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference	GlobeNewsWire
Monday, 13 September 2021
16:10	Eliem Therapeutics Reports Second Quarter Financial Results	GlobeNewsWire
Friday, 13 August 2021
20:10	U.S. IPO Weekly Recap: Summer's Last Wave With 2 IPOs	Seeking Alpha

Ideas & Opinions

Seeking Alpha 28 Jun 2024

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
Seeking Alpha 14 Aug 2021

U.S. IPO Weekly Recap: Summer's Last Wave With 2 IPOs

Frequently Asked Questions (FAQ)

What's the price of Eliem Therapeutics stock today?

One share of Eliem Therapeutics stock can currently be purchased for approximately $5.11.
When is Eliem Therapeutics's next earnings date?

Unfortunately, Eliem Therapeutics's (ELYM) next earnings date is currently unknown.
Does Eliem Therapeutics pay dividends?

No, Eliem Therapeutics does not pay dividends.
How much money does Eliem Therapeutics make?

Eliem Therapeutics has a market capitalization of 342.67M.
What is Eliem Therapeutics's stock symbol?

Eliem Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ELYM".
What is Eliem Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Eliem Therapeutics?

Shares of Eliem Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Eliem Therapeutics's key executives?
Eliem Therapeutics's management team includes the following people:
- Mr. Robert W. Azelby M.B.A. Pres, Chief Executive Officer & Director(age: 57, pay: $678,000)
- Ms. Erin M. Lavelle Executive Vice President, Chief Operating Officer & Chief Financial Officer(age: 47, pay: $502,880)
- Ms. Valerie Morisset Ph.D. Chief Scientific Officer and Executive Vice President of R&D(age: 55, pay: $497,150)
How many employees does Eliem Therapeutics have?

As Jul 2024, Eliem Therapeutics employs 9 workers, which is 70% less then previous quarter.
When Eliem Therapeutics went public?

Eliem Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 10 Aug 2021.
What is Eliem Therapeutics's official website?

The official website for Eliem Therapeutics is eliemtx.com.
Where are Eliem Therapeutics's headquarters?

Eliem Therapeutics is headquartered at 23515 NE Novelty Hill Road, Redmond, WA.
How can i contact Eliem Therapeutics?

Eliem Therapeutics's mailing address is 23515 NE Novelty Hill Road, Redmond, WA and company can be reached via phone at 425 276 2300.

Eliem Therapeutics, Inc.

eliemtx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.

425 276 2300

23515 NE Novelty Hill Road
Redmond, WA 98053

CIK: 0001768446
ISIN: US28658R1068
CUSIP: 28658R106